Drug
LN 144
LN 144: highest development phase Phase 1, developed by Iovance Biotherapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Iovance Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| LN-144 NCT06190249 | Phase 1 | Stage IIIB Melanoma |
Latest
No recent events.
Follow LN 144 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.